Browse > Article
http://dx.doi.org/10.3904/kjim.2014.29.5.630

Etanercept for steroid-refractory acute graft versus host disease following allogeneic hematopoietic stem cell transplantation  

Park, Joo Han (Department of Hematology and Oncology, Ajou University School of Medicine)
Lee, Hyo Jung (Department of Hematology and Oncology, Ajou University School of Medicine)
Kim, Sei Rhan (Department of Hematology and Oncology, Ajou University School of Medicine)
Song, Ga Won (Department of Hematology and Oncology, Ajou University School of Medicine)
Lee, Seung Kyong (Department of Hematology and Oncology, Ajou University School of Medicine)
Park, Sun Young (Department of Hematology and Oncology, Ajou University School of Medicine)
Kim, Ki Chan (Department of Hematology and Oncology, Ajou University School of Medicine)
Hwang, Sun Hyuk (Department of Hematology and Oncology, Ajou University School of Medicine)
Park, Joon Seong (Department of Hematology and Oncology, Ajou University School of Medicine)
Publication Information
The Korean journal of internal medicine / v.29, no.5, 2014 , pp. 630-636 More about this Journal
Abstract
Background/Aims: The treatment for steroid-refractory acute graft versus host disease (GVHD) after allogeneic stem cell transplantation (allo-SCT) needs to be standardized. We report our clinical experience with etanercept for steroid-refractory acute GVHD. Methods: Eighteen patients who underwent allo-SCT and presented with steroid-refractory acute GVHD at Ajou University Hospital were studied retrospectively. They were given 25 mg of etanercept subcutaneously twice weekly for 4 weeks. The clinical responses were evaluated with regard to the severity of acute GVHD. Results: The median patient age was 43.5 years. Using nonparametric tests, etanercept had a down-grading effect on acute GVHD (p = 0.005), although no patient experienced complete remission. Partial responses were seen in 80%, 17%, and 57% of grade II to IV patients, respectively. Skin and gut GVHD were well controlled with etanercept, whereas hepatic GVHD was not. Four patients died of fatal infections. No factors affecting the clinical outcome of etanercept were identified. Conclusions: Etanercept has a modest effect on steroid-refractory acute GVHD after allo-SCT, with tolerable side effects.
Keywords
Stem cell transplantation; Graft vs host disease; TNFR-Fc fusion protein;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Weisdorf D, Haake R, Blazar B, et al. Treatment of moderate/ severe acute graft-versus-host disease after allogeneic bone marrow transplantation: an analysis of clinical risk features and outcome. Blood 1990;75:1024-1030.
2 MacMillan ML, Weisdorf DJ, Wagner JE, et al. Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: comparison of grading systems. Biol Blood Marrow Transplant 2002;8:387-394.   DOI   ScienceOn
3 Levine JE, Paczesny S, Mineishi S, et al. Etanercept plus methylprednisolone as initial therapy for acute graft-versus- host disease. Blood 2008;111:2470-2475.   DOI   ScienceOn
4 Kim DH, Sohn SK, Baek JH, et al. Retrospective multicenter study of allogeneic peripheral blood stem cell transplantation followed by reduced-intensity conditioning or conventional myeloablative regimen. Acta Haematol 2005;113:220-227.   DOI   ScienceOn
5 Basara N, Blau WI, Romer E, et al. Mycophenolate mofetil for the treatment of acute and chronic GVHD in bone marrow transplant patients. Bone Marrow Transplant 1998;22:61-65.   DOI   ScienceOn
6 Arai S, Margolis J, Zahurak M, Anders V, Vogelsang GB. Poor outcome in steroid-refractory graft-versus-host disease with antithymocyte globulin treatment. Biol Blood Marrow Transplant 2002;8:155-160.   DOI   ScienceOn
7 Markey KA, Burman AC, Banovic T, et al. Soluble lymphotoxin is an important effector molecule in GVHD and GVL. Blood 2010;115:122-132.   DOI   ScienceOn
8 Bacigalupo A. Management of acute graft-versus-host disease. Br J Haematol 2007;137:87-98.   DOI   ScienceOn
9 Uberti JP, Ayash L, Ratanatharathorn V, et al. Pilot trial on the use of etanercept and methylprednisolone as primary treatment for acute graft-versus-host disease. Biol Blood Marrow Transplant 2005;11:680-687.   DOI   ScienceOn
10 Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. diagnosis and staging working group report. Biol Blood Marrow Transplant 2005;11:945-956.   DOI   ScienceOn
11 Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus Conference on acute GVHD grading. Bone Marrow Transplant 1995;15:825-828.
12 Wolff D, Roessler V, Steiner B, et al. Treatment of steroid- resistant acute graft-versus-host disease with daclizumab and etanercept. Bone Marrow Transplant 2005;35:1003-1010.   DOI   ScienceOn
13 Maeda Y, Levy RB, Reddy P, et al. Both perforin and Fas ligand are required for the regulation of alloreactive CD8+ T cells during acute graft-versus-host disease. Blood 2005;105:2023-2027.   DOI   ScienceOn
14 Herve P, Flesch M, Tiberghien P, et al. Phase I-II trial of a monoclonal anti-tumor necrosis factor alpha antibody for the treatment of refractory severe acute graft-versushost disease. Blood 1992;79:3362-3368.
15 Hattori K, Hirano T, Miyajima H, et al. Differential effects of anti-Fas ligand and anti-tumor necrosis factor alpha antibodies on acute graft-versus-host disease pathologies. Blood 1998;91:4051-4055.
16 Mollee P, Morton AJ, Irving I, Durrant S. Combination therapy with tacrolimus and anti-thymocyte globulin for the treatment of steroid-resistant acute graft-versus-host disease developing during cyclosporine prophylaxis. Br J Haematol 2001;113:217-223.   DOI   ScienceOn
17 Kennedy GA, Butler J, Western R, Morton J, Durrant S, Hill GR. Combination antithymocyte globulin and soluble TNFalpha inhibitor (etanercept) +/- mycophenolate mofetil for treatment of steroid refractory acute graft-versus- host disease. Bone Marrow Transplant 2006;37:1143-1147.   DOI   ScienceOn